JAMA Neurology | Original Investigation

Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel A Meta-analysis

Brian W. Kunkle, PhD, MPH; Michael Schmidt, PhD; Hans-Ulrich Klein, PhD; Adam C. Naj, PhD;
Kara L. Hamilton-Nelson, MPH; Eric B. Larson, MD, MPH; Denis A. Evans, PhD; Phil L. De Jager, MD, PhD;
Paul K. Crane, MD, MPH; Joe D. Buxbaum, PhD; Nilufer Ertekin-Taner, MD, PhD; Lisa L. Barnes, PhD;
M. Daniele Fallin, PhD; Jennifer J. Manly, PhD; Rodney C. P. Go, PhD; Thomas O. Obisesan, MD;
M. Ilyas Kamboh, PhD; David A. Bennett, MD; Kathleen S. Hall, PhD; Alison M. Goate, DPhil;
Tatiana M. Foroud, PhD; Eden R. Martin, PhD; Li-San Wang, PhD; Goldie S. Byrd, PhD; Lindsay A. Farrer, PhD;
Jonathan L. Haines, PhD; Gerard D. Schellenberg, PhD; Richard Mayeux, MD, MSc;
Margaret A. Pericak-Vance, PhD; Christiane Reitz, MD, PhD;
and the Writing Group for the Alzheimer's Disease Genetics Consortium (ADGC)

IMPORTANCE Compared with non-Hispanic White individuals, African American individuals from the same community are approximately twice as likely to develop Alzheimer disease. Despite this disparity, the largest Alzheimer disease genome-wide association studies to date have been conducted in non-Hispanic White individuals. In the largest association analyses of Alzheimer disease in African American individuals, *ABCA7*, *TREM2*, and an intergenic locus at 5q35 were previously implicated.

OBJECTIVE To identify additional risk loci in African American individuals by increasing the sample size and using the African Genome Resource panel.

DESIGN, SETTING, AND PARTICIPANTS This genome-wide association meta-analysis used case-control and family-based data sets from the Alzheimer Disease Genetics Consortium. There were multiple recruitment sites throughout the United States that included individuals with Alzheimer disease and controls of African American ancestry. Analysis began October 2018 and ended September 2019.

MAIN OUTCOMES AND MEASURES Diagnosis of Alzheimer disease.

RESULTS A total of 2784 individuals with Alzheimer disease (1944 female [69.8%]) and 5222 controls (3743 female [71.7%]) were analyzed (mean [SD] age at last evaluation, 74.2 [13.6] years). Associations with 4 novel common loci centered near the intracellular glycoprotein trafficking gene *EDEM1* (3p26; $P = 8.9 \times 10^{-7}$), near the immune response gene *ALCAM* (3q13; $P = 9.3 \times 10^{-7}$), within GPC6 (13q31; $P = 4.1 \times 10^{-7}$), a gene critical for recruitment of glutamatergic receptors to the neuronal membrane, and within VRK3 (19q13.33; $P = 3.5 \times 10^{-7}$), a gene involved in glutamate neurotoxicity, were identified. In addition, several loci associated with rare variants, including a genome-wide significant intergenic locus near IGF1R at 15q26 ($P = 1.7 \times 10^{-9}$) and 6 additional loci with suggestive significance $(P \le 5 \times 10^{-7})$ such as API5 at 11p12 ($P = 8.8 \times 10^{-8}$) and RBFOX1 at 16p13 ($P = 5.4 \times 10^{-7}$) were identified. Gene expression data from brain tissue demonstrate association of ALCAM, ARAP1, GPC6, and RBFOX1 with brain β-amyloid load. Of 25 known loci associated with Alzheimer disease in non-Hispanic White individuals, only APOE, ABCA7, TREM2, BIN1, CD2AP, FERMT2, and WWOX were implicated at a nominal significance level or stronger in African American individuals. Pathway analyses strongly support the notion that immunity, lipid processing, and intracellular trafficking pathways underlying Alzheimer disease in African American individuals overlap with those observed in non-Hispanic White individuals. A new pathway emerging from these analyses is the kidney system, suggesting a novel mechanism for Alzheimer disease that needs further exploration.

CONCLUSIONS AND RELEVANCE While the major pathways involved in Alzheimer disease etiology in African American individuals are similar to those in non-Hispanic White individuals, the disease-associated loci within these pathways differ.

JAMA Neurol. 2021;78(1):102-113. doi:10.1001/jamaneurol.2020.3536 Published online October 19, 2020. Corrected on March 22, 2021. Supplemental content

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The Alzheimer's Disease Genetics Consortium (ADGC) writing group and collaborators are listed at the end of this article.

Corresponding Authors: Brian W. Kunkle, PhD, MPH, John P. Hussman Institute for Human Genomics and Dr. John T. MacDonald Foundation, Department of Human Genetics, Miller School of Medicine, University of Miami, 1501 NW 10th Ave, Miami, FL 33136 (bkunkle@miami.edu); Christiane Reitz, MD, PhD, Departments of Neurology and Epidemiology, Sergievsky Center, Taub Institute for Research on the Aging Brain, Columbia University, 630 W 168th St, New York, NY 10032 (cr2101@cumc.columbia.edu). arge-scale genomic studies identified more than 20 modest-effect Alzheimer disease (AD) risk loci besides the *APOE* gene.¹⁻⁸ However, these studies were predominantly conducted in individuals of non-Hispanic White ancestry and, taken together, the identified loci explain only 30% to 40% of the genetic contribution to AD,^{9,10} substantially less than the heritability estimates from twin studies ranging from 60% to 80%.¹¹ Compared with non-Hispanic White individuals, African American individuals from the same community are twice as likely to develop AD.¹² Supporting the notion that there are many genetic loci with small effect sizes contributing to these observed ancestral differences in disease risk, we recently demonstrated that AD cases in African American individuals show higher levels of African ancestry than unaffected individuals, both globally and locally at AD-relevant loci.¹³

Various additional observations provide support for the genetic architecture of AD being partially ancestry-specific. In the largest genome-wide association study conducted to date and to our knowledge in African American individuals comprising 5896 participants from the Alzheimer Disease Genetics Consortium, we previously confirmed ABCA7 and APOE, notably with substantial differences in odds ratios compared with non-Hispanic White individuals, and identified a novel intergenic locus at 5q35.¹⁴ Of the additional common loci originally discovered in data sets of non-Hispanic White individuals, only a subset (CR1, BIN1, EPHA1, CD33, TREM2) replicated with nominal significance.^{14,15} Importantly, the population differences in the effect of APOE E4 appear to be explained by the ancestral background on which the allele lies, as we have recently shown that APOE £4 alleles on an African background confer lower risk than those on a non-Hispanic White background.¹⁶ Population-specific associations with AD in rare or low-frequency variants also have been identified. Several rare risk variants found in non-Hispanic White individuals do not show association with risk in African American individuals, possibly because they are extremely rare in African American individuals.^{15,17} In a recent targeted sequencing study of ABCA7, we identified a novel 44 base pair frameshift deletion (rs142076058) in ABCA7 in the same linkage disequilibrium block as the African American individuals' variant (rs115550680) identified by our previous genome-wide association study (GWAS)¹⁸ that is common and associated with disease in African American individuals but present in very few non-Hispanic White individuals (minor allele frequency [MAF] = 0.12%). Two additional missense variants in ABCA7 have been associated with AD in a separate African American population.¹⁹ Finally, separate association studies of AD in African American individuals identified novel rare and low-frequency associations in AKAP9,²⁰ COBL, and SLC10A2²¹ that appear specific to African American individuals. Neuropathologic differences in AD between populations²²⁻²⁶ may also point toward population-specific risk loci for AD. The aim of the present analyses is to identify additional loci modulating risk in African American individuals.

Methods

To identify additional AD risk loci in African American individuals, we conducted a GWAS meta-analysis with a 37% in-

jamaneurology.com

Key Points

Question What genetic variants, genes, and pathways increase or decrease risk of Alzheimer disease in African American individuals?

Findings In this genome-wide association meta-analysis of 2748 individuals with Alzheimer disease and 5222 controls, several novel genetic loci and pathways associated with Alzheimer disease in African American individuals were identified.

Meaning While the major pathways involved in Alzheimer disease etiology in African American individuals are largely similar to those in non-Hispanic White individuals, many of the disease-associated loci within these pathways differ.

creased sample size including individuals with AD and controls recruited from several case-control and family-based studies of African American individuals. A detailed description of the original cohorts and summary demographics of all samples included in this analysis are provided in the eAppendix and eTables 1-3 in Supplement 1. Written informed consent was obtained from all participants, and all study protocols were approved by the respective institutional review boards. Imputation was performed with the African Genome Resources panel,²⁷ which contains all African and non-African populations from 1000 Genomes phase 3 and more than 2000 individuals from various African regions, providing better coverage of ancestral haplotypes than the 1000 Genomes-based reference panels used in previous studies. In line with this notion, comparison of imputation quality of 1000 Genomes and African Genome Resources vs available wholeexome sequencing data in 800 participants demonstrated higher accuracy in the African Genome Resources (eTable 2 in Supplement 1). The final single-nucleotide variant set for analysis included 29 610 185 genotyped and imputed variants, more than doubling the number of variants from our previous analysis.¹⁴ Genotype dosages were analyzed within each data set and subsequently meta-analyzed, adjusting for age, sex, and PCs for population substructure (model 1), and subsequently in addition for APOE genotype (model 2). Additional details on these analyses and the methods for gene, pathway, and expression association analyses can be found in the eMethods in Supplement 1. P values were 2-sided, and the standard GWAS threshold of 5×10^{-8} was used to define genomewide significance. Analysis started October 2018 and ended September 2019.

Results

A total of 2784 individuals (1944 female [69.8%]) with AD and 5222 (3743 female [71.7%]) were analyzed (mean [SD] age at last evaluation, 74.2 [13.6] years). Single-variant meta-analyses replicated the *APOE* locus and both African American individuals' risk loci (rs115550680 [*ABCA7*] and rs145848414 [5q35]) from our previous analyses at $P < 5 \times 10^{-6}$ (**Table 1** and **Figure**).¹⁴ In addition, single-marker meta-analyses yielded 1 novel genome-wide significant ($P \le 5 \times 10^{-8}$) disease locus associated with rare

lable I. Kesu	Its of SV Meta-	analysis												
			Maior/		Model 1 ^a				Model 2 ^b				NHW P	alue ^c
Closest gene(s)	Marker	dbSNP	minimum allele	MAF	OR (95% CI)	P value	Direction ^d	P value for <i>I</i> ² , %	OR (95% CI)	P value	Direction ^d	P value for <i>I</i> ² , %	SV	Gene
Novel comm	on loci													
EDEM1	3:5302077	rs168193	A/G	0.25	0.79 (0.72-0.87)	8.9×10^{-7}	-++	0.50	0.81 (0.74-0.90)	9.0×10^{-5}	-+++	.48	.47	.90
ALCAM	3:104409208	: rs2633682	C/A	0.33	0.78 (0.71-0.86)	9.3×10^{-7}	ż	0.86	0.85 (0.78-0.92)	2.0×10^{-4}		.78	.61	.64
GPC6	13:94159800	rs9516245	T/C	0.04	1.61 (1.32-1.96)	2.5×10^{-6}	+++++++++++++++++++++++++++++++++++++++	0.22	1.73 (1.39-2.15)	4.0×10^{-7}	+++++++++++++++++++++++++++++++++++++++	.15	.94	.04
VRK3	19:50524332	rs3745495	A/G	0.10	1.32 (1.17-1.48)	7.4×10^{-6}	-+-+-++-	0.21	1.39 (1.23-1.56)	3.5×10^{-7}	-+++-	60.	.37	.31
Novel rare lo	ci													
SIPA1L2	1:232376163	^e rs115684722	A/T	0.01	12.6 (4.66-34.45)	6.3×10^{-7}	+ ¿¿ ¿ + + + ¿ + ¿ + + + ¿	0.70	3.70 (1.59-8.60)	2.4×10^{-3}	+¿¿¿+++¿¿+++¿¿	.35	.29	.32
WDR70	5:37483940	rs184179037	C/T	0.006	5.00 (2.27-9.18)	1.8×10^{-7}	2222+++2++2+++	0.64	5.41 (2.78-10.55)	4.6×10^{-7}	¿¿¿? ++? ++? +++	.38	.05	.18
API5	11:43166842	°rs569584007	1/G	0.01	3.06 (1.26-7.40)	.013	+¿+¿+++¿¿+¿¿¿¿	0.92	10.48 (4.42-24.83)	8.8×10^{-8}	+¿+¿+++¿¿+¿¿¿¿	.07	ЧN	98.
ACER3	11:76541840	^{1e} rs115816806	A/G	0.01	4.71 (2.15-10.31)	1.0×10^{-4}	+¿¿¿¿÷÷+÷-+-¿	0.42	6.55 (3.17-13.53)	5.1×10^{-7}	+¿¿¿¿++¿++¿+-¿	.15	NP	.28
PIK3C2G	12:18471546	rs75739461	G/A	0.01	2.45 (1.59-3.78)	3.0×10^{-5}	+¿¿¿+++-++;+++	0.94	3.03 (1.93-4.76)	9.9×10^{-7}	+¿¿¿+++-++;++-	.88	NP	.03
ARRDC4	15:97992685	^c rs570487962	NA	0.01	0.20 (0.10-0.37)	6.4×10^{-7}	22-22+-2+-2-22	0.32	0.10 (0.05-0.22)	1.6×10^{-9}	<u> خز-خز+-خ</u> +-خ	.10	NP	0.25
IGF1R														0.93
RBFOX1	16:8288401	rs79537509	G/T	0.007	3.85 (2.22-6.67)	1.5×10^{-6}	+¿¿¿+++;++++	0.69	4.61 (2.51-8.47)	5.3×10^{-7}	+¿¿¿+++;++++;-	.67	.07	.84
Loci reported	in Reitz et al ¹⁴													
NSG2				000		9-07 7		.000		9-0-E		T C	4	0.04
MSX2	- 5:1/4UI4II4	Frs145848414	A/b	0.03	(62.2-14.1)8/.1	2 NT x C.T	+++;+++++++++++++++++++++++++++++++++++	U.94	1.Ub (U.83-1.34)	2.0 × 10	+++;+++++++++++++++++++++++++++++++++++	/ 8.	L L	0.66
ABCA7	19:1050420	rs115550680	A/G	0.07	1.41 (1.21-1.65)	3.2×10^{-5}	-++++++++++++++++++++++++++++++++++++++	0.08	1.58 (1.32-1.88)	4.0×10^{-7}	+++++++++++++++++++++++++++++++++++++++	.07	NP	1.8×10^{-12}
APOE	19:45423934	: rs157591	G/A	0.12	1.93 (1.72-2.17)	1.8×10^{-25}	+++++++++++++++++++++++++++++++++++++++	0.20	0.94 (0.80-1.10)	.485	++++	.37	ЧN	1.4×10^{-154}
Abbreviations	: dbSNP, Single I	Nucleotide Polyr	norphism Da	atabase; M	1AF, minor allele frequ	iency;	c P valu	ue for NHW i	ndividuals' SV and gei	ne-based test	s adjusted for PCs, age,	and sex.		
NA, not applic	able; NHW, non	-Hispanic White;	; NP, not pre:	sent; OR, c	odds ratio; SV, single v	/ariant.	^d Study	/-specific dir	ection of the single-n	ucleotide vari	ant β coefficient.			
^a Model 1 is ad	justed for PCs, a,	ge, and sex.					^e Variai	nt was not a	ssessed in Reitz et al. ¹	4				
^b Model 2 is ac	ljusted for PCs, ä	ige, sex, and AP(OE genotype	c;										

104 JAMA Neurology January 2021 Volume 78, Number 1

Downloaded From: https://jamanetwork.com/ on 08/27/2022







Manhattan plots showing negative log₁₀-transformed *P* values from the single-variant meta-analysis adjusted for age, sex, and population stratification (A, model 1) and age, sex, population stratification, and *APOE* (B, model 2). The horizontal lines represent the genome-wide significance threshold

 $(P = 5 \times 10^{-8}; \text{red})$ and suggestive threshold $(P = 1 \times 10^{-6}; \text{orange})$. Loci are labeled with the closest gene(s) to the sentinel variant. Known loci are in blue and novel loci are in red. The *y*-axis is truncated, and the lowest *P* value on chromosome 19 was 1.8×10^{-25} .

variants and 10 novel disease-associated loci (4 common variant loci, 6 rare variant loci) associated at $P \le 5 \times 10^{-7}$ (Table 1; eFigures 1-2 in Supplement 1). There was no evidence for genomic inflation (model 1: $\lambda = 0.94$; model 2: $\lambda = 0.96$); see eFigure 3 in Supplement 1 for QQ plots). The 4 common loci were centered at (1) *EDEM1* on chromosome 3p26 (rs168193; MAF = 0.25; $P = 8.9 \times 10^{-7}$), a known linkage region for AD,²⁸ (2) *ALCAM* on chromosome 3q13 (rs2633682; MAF = 0.33; $P = 9.3 \times 10^{-7}$), (3) within *GPC6* on chromosome 13q31 (rs9516245; MAF = 0.04; $P = 4.1 \times 10^{-7}$), and (4) within *VRK3* on chromosome 19q13.33

(rs3745495; MAF = 0.10; $P = 3.5 \times 10^{-7}$). Three of 4 loci have strong regional support by variants in linkage disequilibrium (eFigure 1A in Supplement 1), and all 4 have consistent directions of effect across most individual data sets (eFigure 2A in Supplement 1). While *VRK3* is located approximately 5 megabases downstream of *APOE*, the *APOE*-adjusted model and analyses showing that rs3745495 is not in linkage disequilibrium with variants within *APOE* (eFigure 4 in Supplement 1) suggest that it represents an independent AD-associated signal in African American individuals. The identified rare variants include a

jamaneurology.com

Table 2. Novel Top Loci Identified in Gene-Based Analyses

					Model 1 ^a			Model 2 ^b			
Gene	Chromosome	Start BP (hg37)	Stop BP (hg37)	No.	No. of SNVs	z Statistic	P value	No. of SNVs	z Statistic	P value	Pathway
TRANK1	3	36 858 311	37 021 548	7984	1221	2.83	2.2 × 10 ⁻³	1201	3.83	6.4×10^{-5}	Neuronal development
FABP2	4	120 228 405	120 278 545	7984	411	2.66	3.8×10^{-3}	452	4.00	3.1×10^{-5}	Lipid metabolism
LARP1B	4	128 947 423	129 154 086	7984	1071	4.11	1.9×10^{-5}	1334	1.93	2.6×10^{-2}	RNA transcription
TSRM	7	113 056 127	113 101 457	7984	334	3.62	1.4×10^{-4}	334	4.02	2.7 × 10 ⁻⁵	Zinc finger domain-related protein
ARAP1	11	72 386 114	72 539 644	7984	1294	3.74	9.1 × 10 ⁻⁵	1281	3.62	1.4 × 10 ⁻⁴	Endocytosis/intracellular trafficking
STARD10	11	72 455 774	72 539 726	7984	664	3.94	3.9×10^{-5}	660	3.50	2.3×10^{-4}	Lipid metabolism
SPHK1	17	74 337 665	74 393 941	7984	485	3.73	9.3×10^{-5}	482	3.48	2.5×10^{-4}	Immune response
SERPINB13	18	61219223	61 281 873	7984	633	3.10	9.4 × 10 ⁻⁴	626	3.79	7.4 × 10 ⁻⁵	Protease inhibition, immune response

Abbreviations: BP, base pair; SNV, single-nucleotide variant.

^a Model 1 is adjusted for PCs, age, and sex.

^b Model 2 is adjusted for PCs, age, sex, and APOE genotype.

genome-wide significant intergenic locus at 15q26 close to *ARRDC4* and *IGF1R* (rs570487962; MAF = 0.01; $P = 1.69 \times 10^{-9}$) and 6 loci with associations of $P < 5 \times 10^{-7}$ close to *SIPA1L2*, *WDR70*, *API5*, *ACER3*, *PIK3C2G*, and *RBFOX1* (Table 1 and eFigures 1 and 2 in Supplement 1). Repeating the analyses stratified by *APOEe4* carrier status revealed the association with *RBFOX1* was only present in cases without an *APOEe4* allele, while the intergenic association at *ARRDC4/IGF1R* was only found in carriers of the *APOEe4* allele (eTables 4-5 in Supplement 1). These results should be interpreted with caution because of the small sample sizes obtained after stratification on *APOEe4* status (eTable 5 in Supplement 1).

Of the variants previously implicated in AD in African American individuals by other studies, ^{15,17,20,21} rs112404845 in *COBL* showed association ($P = 5.4 \times 10^{-6}$), and 2 variants each in *TREM2* (rs7748513; $P = 3.6 \times 10^{-5}$ and rs2234256; P = .001) and *AKAP9* (rs149979685; P = .005 and rs914662445; P = .01) were replicated with at P < .05 (eTable 6 in Supplement 1). A low-frequency *TREM2* stop-gain variant previously reported at P = .08 in a sample of 906 load cases and 2487 controls, was associated at $P = 1.4 \times 10^{-3}$ (rs2234258).¹⁷ Of the GWAS loci implicated in non-Hispanic White individuals besides *APOE* and *ABCA7*,⁷ only the variants in *BIN1* ($P = 9 \times 10^{-4}$), *CD2AP* (P = .02), *FERMT2* (P = .01), and *WWOX* (P = .04) showed nominal association in this African American sample (eTable 6 in Supplement 1).

Gene-Based Analyses

Gene-based analyses confirmed at gene-wide significance the *TREM2* gene, originally identified in non-Hispanic White populations,^{5,29} as an AD risk locus in African American individuals ($P = 9.89 \times 10^{-6}$) and identified $8 \operatorname{loci}(TRANK1, FABP2, LARP1B, TSRM, ARAP1, STARD10, SPHK1, and SERPINB13$) with associations of $P \leq 1 \times 10^{-4}$ (Table 2 and eFigure 2 in Supplement 1). Of the other risk loci previously reported in African American or non-Hispanic White individuals besides *TREM2*, only *C2DAP* (P = .03) was significant at $P \leq .05$ (eTable 7 in Supplement 1). Full summary statistics for the complete set of single-marker and gene-based analyses are available through

the National Institute on Aging Genetics of Alzheimer Disease Data Storage Site. $^{\rm 30}$

Validation and Prioritization of Identified Loci

To validate the identified loci and evaluate their biological significance, we examined differential expression of amyloid and tau pathology in AD vs control brains and conducted pathway analyses.

To explore differential expression, we capitalized on postmortem brain pathology quantified by immunohistochemistry and expression data from 478 individuals of European ancestry from the ROS/MAP study.³¹ Covarying for sex, age at death (age at last visit for clinical AD diagnosis), postmortem interval, RNA integrity, APOE ε4 status, and first 3 genomic principal components, higher expression of ALCAM (β = 0.038; *P* = .003) and *ARAP1* (β = 0.058; *P* = 2.0 × 10⁻⁴) and lower expression of GPC6 ($\beta = -0.035$; P = .001) and RBFOX1 $(\beta = -0.055; P = .001)$ were associated with brain amyloid load after correction for multiple testing (Table 3; Bonferroni P value threshold for significance: P = .05/19 tested genes = .003). Higher expression of STARD10 was associated with higher tau pathology burden ($\beta = 0.050$; $P = 8.46 \times 10^{-5}$). When covarying in addition for differences in cell type composition across samples, associations for ALCAM ($\beta = 0.033$; P = .004), ARAP1 $(\beta = 0.06; P = 9.3 \times 10^{-6}), GPC6 (\beta = -0.034; P = .002), and$ *RBFOX1* (β = -0.050; *P* = .001) with brain amyloid load remained unchanged; association of STARD10 with tau pathology burden was slightly attenuated ($\beta = 0.03$; P = .01).

Pathway analyses conducted using Multi-marker Analysis of GenoMic Annotation³² identified 8 main functional groups at $P < 1 \times 10^{-3}$ (**Table 4**): (1) intracellular trafficking, (2) lipid and phospholipid metabolism, (3) transcription/ DNA repair, (4) nervous system development/synaptic plasticity, (5) cell division, (6) immune response, (7) cellular signaling, and (8) kidney system development. With the exception of kidney system development, these pathways overlap with the key molecular mechanisms identified in the large-scale genomic studies in non-Hispanic White individuals.^{7,33} However, enrichment of amyloid precursor protein/amyloid (A)- β

	Tat	ole 3	. Association of	Gene Expression	1 at Suggestive Lo	ci With Neuropath	ological Measures	of Alzheimer Disea	se in the ROS/MAP Data Set ³¹
--	-----	-------	------------------	-----------------	--------------------	-------------------	-------------------	--------------------	--

			Amyloid pathology		Tau pathology	
Chromosome	Band	Symbol	β ^a	P value	β ^a	P value
1	q42.2	SIPA1L2	-0.004	.72	-0.018	.08
3	p22.2	TRANK1	-0.057	.005	-0.046	.007
3	p26.1	EDEM1	0.002	.84	-0.022	.01
3	q13.11	ALCAM	0.038	.003	-0.023	.03
4	q26.2	FABP2	Not detected in DLPFC		Not detected in DLPFC	
4	q28.2	LARP1B	-0.017	.21	0.019	.10
5	p13.2	WDR70	-0.028	.05	0.036	.004
11	p12	API5	0.009	.24	-0.013	.04
11	q13.4	ARAP1	0.058	2.0×10^{-4}	0.019	.11
11	q13.4	STARD10	0.005	.71	0.050	8.46 × 10 ⁻⁵
11	q13.5	ACER3	0.027	.08	-0.002	.91
12	p12.3	PIK3C2G	-0.011	.09	-0.001	.88
13	q31.3	GPC6	-0.035	.001	0.001	.91
15	q26.2	ARRDC4	0.017	.32	-0.023	.11
15	q26.2	IGF1R	0.031	.005	-0.005	.61
16	p13.3	RBFOX1	-0.055	.001	0.008	.57
17	q25.2	SPHK1	0.067	.01	0.015	.50
18	q21.33	SERPINB13	Not detected in DLPFC		Not detected in DLPFC	
19	q13.33	VRK3	-0.001	.91	-0.022	.03

Abbreviation: DLPFC, dorsolateral prefrontal cortex.

increased pathology burden in the presence of higher gene expression, and a negative β coefficient reflects an inverse association.

 a β Coefficient for the association between the expression of the gene and amyloid or tau pathology is reported. A positive β coefficient reflects an

and tau pathways, which recently emerged as top molecular pathways in the large-scale rare variant meta-analysis in non-Hispanic White individuals conducted by the International Genomics of Alzheimer Project (IGAP),⁷ are notably absent among the top disease-associated pathways observed in this data set of African American individuals.

Examination of Identified Single-Variant, Gene-Based, and Pathway Associations in the IGAP Data Set of Non-Hispanic White Individuals

Comparison of the top single-variant associations in African American individuals with the results of the latest GWAS of non-Hispanic White individuals from the IGAP consortium $(n = 94437)^7$ revealed nominal replication of the singlevariant association in the WDR70 gene (P = .05) and nearly nominal replication of the RBFOX1 locus (P = .07) (eTable 8 in Supplement 1). Gene-based testing of loci resulting from the single-variant analysis of African American individuals revealed PIK3C2G and GPC6 to have significance at P < .05. For the gene-based loci, the only result with nominal replication in IGAP was STARD10 (P = .02), although ARAP1 also approached significance at P < .05. Of the 21 pathways associated at $P < 10^{-4}$ in African American individuals, only 2 replicated at a nominal level: inositol tetrakisphosphate phosphatase activity (P = .02) and positive regulation of nuclear division (P = .05), suggesting that while the major pathways are similar between African American and non-Hispanic White individuals, the subpathways defining these functions may differ slightly because of the specific genes involved.

Discussion

In the largest AD GWAS study on African American individuals conducted to date and to our knowledge, we confirmed ABCA7, the intergenic locus on chromosome 5q35, and several variants in or near COBL, TREM2, and AKAP9 as associated with AD and identified 1 novel genome-wide significant disease locus and 10 novel disease-associated loci associated at $P \le 5 \times 10^{-7}$. Gene-based analyses also confirmed *TREM2* as a risk locus in this population and nominated 8 additional loci with associations of $P \le 1 \times 10^{-4}$. For 4 of these 8 novel loci, gene expression analysis from brain tissue demonstrated significant association with burden of brain amyloid (ALCAM, ARAP1, GPC6, RBFOX1), a key pathological hallmark of AD. Of 25 known loci in non-Hispanic White individuals,^{7,34} only APOE, ABCA7, TREM2, BIN1, CD2AP, FERMT2, and WWOX were implicated at a nominal significance level or stronger in this African American sample.

Notably, the majority of novel loci identified in this study cluster in pathways was also implicated in non-Hispanic White individuals. The 4 common loci that were, because of their high allele frequencies, robustly present in all contributing data sets, cluster near or in genes involved in intracellular trafficking, immune response, and glutamatergic synaptic transmission. *EDEM1*, located in a known AD linkage region (3q26),³⁵ encodes a protein that sequesters misfolded proteins, including the amyloid precursor protein, away from productive folding cycles and redirects them to endoplasmic reticulum-

jamaneurology.com

10.11

Table 4. Top Associated Pathways Derived From MAGMA Pathway Analysis								
Pathway (GO)	Model	No. of	Pivalue	Pathway description				
G0:0045898	2	13	2.0×10^{-5}	Transcription				
GO:0051004	1	15	4.9 × 10 ⁻⁵	Lipoprotein metabolism				
GO:0072017	1, 2	12	1.0×10^{-4}	Kidney system development				
GO:0072207	1	20	2.2 × 10 ⁻⁴	Kidney system development				
GO:0033363	1	27	3.4×10^{-4}	Intracellular trafficking				
GO:0015693	2	11	3.4×10^{-4}	Magnesium ion transport				
GO:0048169	1	23	3.5×10^{-4}	Synaptic plasticity				
GO:0051785	2	62	4.3×10^{-4}	Cell division				
GO:0009395	1	29	4.6×10^{-4}	Phospholipid metabolism				
GO:0006266	2	16	4.7×10^{-4}	DNA repair				
GO:0042493	2	422	5.2×10^{-4}	Drug response				
G0:0044304	2	58	5.6×10^{-4}	Nervous system development				
GO:1903533	1	296	5.7×10^{-4}	Intracellular trafficking				
GO:0052743	1	10	6.5×10^{-4}	ITPKB/Ins(1,3,4,5)P4/ERK signaling				
GO:0051717	1	10	6.5×10^{-4}	Cellular signaling				
GO:1990782	1	55	6.5×10^{-4}	Cellular signaling				
GO:0002281	2	11	6.6×10^{-4}	Immune response				
GO:0046475	1	13	7.3×10^{-4}	Phospholipid metabolism				
GO:0051103	2	12	8.4×10^{-4}	DNA repair				
GO:0032386	1	597	8.8×10^{-4}	Intracellular trafficking				
GO:0008143	2	12	9.3×10^{-4}	Transcription				
GO:0045840	1	51	9.7×10^{-4}	Cell division				

Abbreviations: ERK, extracellular signal-related kinase; MAGMA, Multi-marker Analysis of GenoMic Annotation.

associated degradation.³⁶⁻³⁸ There is evidence that upregulation of endoplasmic reticulum-associated degradation leads to amyloid precursor protein degradation and reduced AB production.³⁹ ALCAM encodes CD166 antigen promoting Tcell activation, maturation of the immunological synapse, and axon growth. A recent GWAS on cognitive decline in older adults free of dementia identified a suggestive signal in the ALCAM gene region (rs34476301; $P = 6.5 \times 10^{-6}$) associated with longitudinal changes in the memory domain.⁴⁰ GPC6 encodes glypican 6 belonging to a conserved family of heparan sulfate proteoglycans. Secreted by astrocytes, GPC6 regulates recruitment of glutamate (GluA1 AMPA) receptors to the neuronal surface and promotes formation of excitatory synapses in neurons.⁴¹ The locus at 19q13 shows different local ancestry with regard to AD status in African American individuals,13 providing significant support for the importance of this region in AD etiology in this ethnic group. The signal falls within VRK3 encoding a serine/threonine kinase modulating the activity of extracellular signal-regulated kinases⁴² involved in the regulation of synaptic protein synthesis, dendritic morphology, and synaptic plasticity.43,44 Dysregulation of glutamate-induced extracellular signal-regulated kinase signaling via VRK3 is associated with Aβ accumulation,⁴⁵ and VRK3 itself has been suggested as a potential therapeutic target for AD.⁴⁵ In expression data from the ROS/MAP study,³¹ ALCAM and GPC6 expression was associated with amount of brain amyloid pathology. Codeposition and association of various heparan sulfate proteoglycans with $A\beta$ has long been described,⁴⁶⁻⁴⁸ and in vitro studies have shown that heparan sulfate proteoglycans can regulate A_β production^{49,50} and aggregation.49,51

The 7 identified rare variant loci include the 2 top loci identified in this study, centered in a noncoding RNA (LINC02254) near the *IGF1R* gene on chromosome 15q26 ($P = 1.69 \times 10^{-9}$) and API5 on chromosome 11p12 ($P = 8.81 \times 10^{-8}$). The associated variants near IGF1R are all African-specific according to the Genome Aggregation Database.⁵² Interestingly, a GWAS of cognitive flexibility, an AD-linked phenotype,⁵³ identified a genome-wide significant association approximately 80 kilobases upstream of this rare variant signal in African American individuals but not in non-Hispanic White individuals,⁵⁴ lending support to this locus as an AD locus specific to African American individuals. *IGF1R* is a receptor for insulinlike growth factor I (IGF-I) controlling stress resistance, aging, and lifespan.⁵⁵ Brains of individuals with AD show abnormalities in IGF1R expression and downstream signaling molecules, insulin and IGF1 resistance, ^{56,57} and long-term inhibition of IGF signaling supports neuronal function and neuroprotection.^{57,58} Lifespan-extending heterozygous IGF1R knockout alleviates AD pathology through Aβ clearance,⁵⁶ confers neuroprotection against Aβ proteotoxicity, and improves behavior in mice with AD.^{59,60} In this study, association of *IGF1R* expression with amyloid load was close to Bonferroni-corrected significance (*P* = .005). Apoptosis inhibitor-5 (*API5*) is a nuclear protein highly expressed in the brain whose expression prevents apoptotic cell death.⁶¹

While the top disease-associated variant at the chromosome 16p13 locus is located approximately 500 kilobases downstream of *RBFOX1*, analysis of expression data and findings from epidemiologic, animal, and experimental studies nominate *RBFOX1* as a potential candidate gene at this locus that warrants further scrutiny. *RBFOX1* is a critical regulator of splicing and cytoplasmic mRNA stability in neurons^{62,63} that has been implicated across a series of neurodevelopmental and psychiatric disorders.⁶⁴ There is evidence from experimental studies that downregulation of *RBFOX1* leads to destabilization of messenger RNAs encoding for proteins involved in synaptic transmission and diminished synaptic function in AD^{65,66} and that *RBFOX1* might regulate splicing of amyloid precursor protein.⁶⁷ Notably, a GWAS of positron emission tomography amyloid levels in individuals without dementia reported by Raghavan et al⁶⁸ nominates *RBFOX1* as a locus for brain amyloidosis, in line with this notion and our GWAS and brain amyloid pathology analyses.

Gene-based analyses confirmed TREM2 as an AD risk gene in African American individuals and identified an additional 8 novel loci with associations of $P \le 1 \times 10^{-4}$ (eFigure 5 in Supplement 1). Notably, also these genes largely cluster in AD pathways implicated by genomic studies in non-Hispanic White populations. While TRANK1 at 3p22.2 is a known GWAS risk locus for bipolar disorder and schizophrenia⁶⁹⁻⁷² and potentially modulates expression of genes involved in neural development and differentiation, 73 FABP2 and STARD10 are involved in lipid metabolism, SPHK1 and SERPINB13 in immune response, LARP1B in RNA transcription, and ARAP1 in endocytosis and intracellular trafficking. Finally, the results of our pathway analyses also support the notion that the principal molecular pathways (eg, immunity, lipid processing, intracellular trafficking) underlying AD in African American individuals overlap with those observed in non-Hispanic White individuals, albeit largely with different disease-associated genes within these pathways. A novel AD pathway emerging from this pathway analyses is kidney system development. This finding is particularly interesting given the observation that African American individuals are 3 times more likely to experience kidney failure compared with the non-Hispanic White population,⁷⁴ and along with Hispanic populations, have a higher rate of comorbidity for dementia and kidney disease.⁷⁵ Impaired kidney clearance of peripherally circulating Aß results in elevated cerebral Aß retention.⁷⁶ Determining the contribution of this comorbid condition to AD risk, and whether misdiagnosis of AD plays a role in this association,⁷⁷ could have important implications for the prevention and treatment of AD in African American individuals.

Compared with our previous analyses based on the 1000 Genomes panel (June 2011), the African Genome Resources reference panel used in the current analysis allowed us to include both a higher number of common variants and a significant set of low-frequency variants previously not included. While some of the newly identified common variants were assessed in the previous analyses but now reached genomewide significance because of increased statistical power, most of the newly identified variants with rarer minor allele frequencies were previously not assessed. For all novel identified disease-associated variants, imputation quality was excellent. There was also no evidence of inflation in our study when including low-frequency variants, minimizing the likelihood that the observed associations are spurious.

Limitations

This study has limitations. First, given the paucity of available African American samples for genomic research on AD and the need to maximize sample size to reach sufficient statistical power to identify variants with low frequency or effect sizes, we combined all samples into 1 discovery set and relied on the IGAP data on non-Hispanic White individuals and ROS/MAP brain expression data sets for replication.^{7,78} Additional validation will likely need to be derived from experimental studies. Second, while this is the largest GWAS data set on African American individuals to date and to our knowledge, our sample size was underpowered to detect associations with very rare single variants or rare variants exerting very small effects. Consequently, it is possible that there remain unidentified disease-associated variants.

Conclusions

Our study strongly suggests that the principal molecular pathways implicated in AD etiology in African American individuals largely overlap with those in non-Hispanic White individuals but that the disease-associated loci within these pathways differ. These observations are critical for several reasons. First, they provide significant support for the importance of native immune response, intracellular trafficking, lipid metabolism, nervous system development, and synaptic plasticity in AD etiology and suggest that these pathways are not ethnicity-specific but critical in disease etiology across ethnic groups. Second, this study suggests that there might also be pathways whose contributions to disease differ between ethnic groups. While amyloid and tau pathology did not emerge as top pathways in this data set on African American individuals, kidney system development was identified as a novel, plausible disease mechanism. Interestingly, cerebrospinal fluid concentrations of tau have been observed to be lower in African American individuals affected with AD compared with non-Hispanic White individuals with AD.²⁴ Finally, these observations strongly suggest that polygenic risk scores developed for non-Hispanic White populations will likely not be applicable to this ethnic group and vice versa but that polygenic risk scores need to be developed and applied as ethnic group-specific. While additional validation is needed, the identified genomic loci and pathways significantly help to disentangle AD etiology in African American individuals, aid to clarify the molecular mechanisms underlying observed health disparities, and help to pinpoint molecular targets for therapeutic intervention in this ethnic group.

ARTICLE INFORMATION

Accepted for Publication: April 9, 2020. Published Online: October 19, 2020. doi:10.1001/jamaneurol.2020.3536 **Correction:** This article was corrected on March 22, 2021, to fix a spelling error in the byline.

Author Affiliations: The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida (Kunkle, Schmidt, Hamilton-Nelson, Martin, Pericak-Vance); Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami, Miami, Florida (Kunkle, Schmidt, Martin, Pericak-Vance); Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York (Klein, De Jager, Manly, Mayeux, Reitz); Gertrude H. Sergievsky

jamaneurology.com

Center, Columbia University, New York, New York (Klein, De Jager, Manly, Mayeux, Reitz); Department of Neurology, Columbia University, New York, New York (Klein, De Jager, Manly, Mayeux, Reitz); Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia (Naj); Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine. Philadelphia (Naj, Crane, Wang, Schellenberg); Department of Medicine, University of Washington, Seattle (Larson): Group Health Research Institute. Group Health, Seattle, Washington (Larson); Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois (Evans); Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois (Evans); Department of Psychiatry, Mount Sinai School of Medicine, New York, New York (Buxbaum); Department of Genetics and Genomics Sciences, Mount Sinai School of Medicine, New York, New York (Buxbaum, Goate); Department of Neuroscience, Mount Sinai School of Medicine, New York, New York (Buxbaum, Goate); Friedman Brain Institute, Mount Sinai School of Medicine, New York, New York (Buxbaum, Goate); Department of Neuroscience, Mayo Clinic, Jacksonville, Florida (Ertekin-Taner); Department of Neurology, Mayo Clinic, Jacksonville, Florida (Ertekin-Taner); Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois (Barnes); Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois (Barnes); Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois (Barnes); Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Marvland (Fallin): Department of Epidemiology, University of Alabama at Birmingham, Birmingham (Go): Howard University, Howard University Hospital, Washington, DC (Obisesan); Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania (Kamboh); Alzheimer's Disease Research Center, University of Pittsburgh. Pittsburgh, Pennsylvania (Kamboh); Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois (Bennett); Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Illinois (Bennett): Department of Psychiatry, Indiana University School of Medicine, Indianapolis (Hall); Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York (Goate); Department of Medical and Molecular Genetics, Indiana University, Indianapolis (Foroud); Maya Angelou Center for Health Equity, Wake Forest School of Medicine, Winston-Salem, North Carolina (Byrd); Department of Medicine (Biomedical Genetics). Boston University School of Medicine. Boston, Massachusetts (Farrer); Department of Neurology, Boston University School of Medicine, Boston, Massachusetts (Farrer); Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts (Farrer): Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts (Farrer); Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts (Farrer): Department of Population and Quantitative Health Sciences, Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio (Haines); Department of

Psychiatry, Columbia University, New York, New York (Mayeux); Epidemiology, College of Physicians and Surgeons, Columbia University, New York, New York (Mayeux, Reitz).

Writing Committee for the Alzheimer's Disease Genetics Consortium (ADGC): Neill R. Graff-Radford, MD; Izri Martinez, MD; Temitope Ayodele, MS; Mark W. Logue, PhD; Laura B. Cantwell, MPH; Melissa Jean-Francois, MPH; Amanda B. Kuzma, MS: L.D. Adams, BA: Jefferv M. Vance, MD, PhD; Michael L. Cuccaro, PhD; Jaeyoon Chung, PhD; Jesse Mez, MD; Kathryn L. Lunetta, PhD; Gyungah R. Jun, PhD; Oscar L. Lopez, MD; Hugh C. Hendrie, MD; Eric M. Reiman, MD; Neil W. Kowall, MD: James B. Leverenz, MD: Scott A. Small. MD; Allan I. Levey, MD, PhD; Todd E. Golde, MD, PhD; Andrew J. Saykin, PsyD; Takiyah D. Starks, MS; Marilyn S. Albert, PhD; Bradley T. Hyman, MD, PhD; Ronald C. Petersen, MD, PhD; Mary Sano, PhD; Thomas Wisniewski, MD: Robert Vassar, PhD: Jeffrey A. Kaye, MD; Victor W. Henderson, MD, MS; Charles DeCarli, MD; Frank M. LaFerla, PhD; James B. Brewer, MD, PhD; Bruce L. Miller, MD; Russell H. Swerdlow, MD; Linda J. Van Eldik, PhD; Henry L. Paulson, MD, PhD; John Q. Trojanowski, MD, PhD; Helena C. Chui, MD; Roger N. Rosenberg, MD; Suzanne Craft, PhD; Thomas J. Grabowski, MD; Sanjay Asthana, MD; John C. Morris, MD; Stephen M. Strittmatter, MD, PhD; Walter A. Kukull, PhD.

Affiliations of Writing Committee for the **Alzheimer's Disease Genetics Consortium** (ADGC): The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida (Jean-Francois, Adams, Vance, Cuccaro); Dr. John T. MacDonald Foundation, Department of Human Genetics, University of Miami, Miami, Florida (Vance, Cuccaro): Gertrude H. Sergievsky Center. Columbia University, New York, New York (Martinez, Ayodele); Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia (Cantwell, Kuzma); Department of Psychiatry, Mount Sinai School of Medicine, New York, New York (Sano); Department of Neuroscience, Mayo Clinic, Jacksonville, Florida (Graff-Radford); Department of Neurology, Mayo Clinic. Jacksonville, Florida (Graff-Radford); Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania (Lopez); Department of Psychiatry, Indiana University School of Medicine, Indianapolis (Hendrie): Department of Medical and Molecular Genetics, Indiana University, Indianapolis (Saykin); Maya Angelou Center for Health Equity, Wake Forest School of Medicine, Winston-Salem, North Carolina (Starks); Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts (Logue, Chung); Department of Neurology, Boston University School of Medicine, Boston, Massachusetts (Mez, Jun); Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts (Lunetta, Jun); Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts (Jun); National Center for PTSD, VA Boston Healthcare System, Boston, Massachusetts (Logue); Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts (Logue); Arizona Alzheimer's Center, Banner Alzheimer's Institute, Phoenix (Reiman): Boston University. Boston VA Medical Center, Jamaica Plain, Massachusetts (Kowall); Cleveland Clinic, Cleveland, Ohio

(Leverenz); Columbia University Alzheimer's Disease Research Center, New York, New York (Small); Department of Neurology, Emory University, Atlanta, Georgia (Levey); Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville (Golde); Indiana Alzheimer Disease Center, Indiana University School of Medicine. Indianapolis (Saykin); Department of Radiology and Imaging Sciences. Indiana University School of Medicine. Indianapolis (Saykin); Johns Hopkins University School of Medicine, Baltimore, Maryland (Albert); Massachusetts Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital, Charlestown (Hyman); Department of Neurology, Mayo Clinic, Rochester, Minnesota (Petersen); Center for Cognitive Neurology, New York University, New York (Wisniewski); Department of Neurology, Northwestern University, Chicago, Illinois (Vassar); Aging & Alzheimer Disease Center, Oregon Health & Science University, Portland (Kaye); Department of Epidemiology & Population Health, Stanford University, Stanford, California (Henderson); Department of Neurology & Neurological Sciences, Stanford University, Stanford, California (Henderson); University of California Davis at Medical Center, Sacramento (DeCarli); University of California Irvine, Irvine, (LaFerla); Shiley-Marcos Alzheimer's Disease Center, UC San Diego, La Jolla. California (Brewer); University of California San Francisco, San Francisco (Miller); Alzheimer's Disease Research Center, University of Kansas. Kansas City (Swerdlow); Sanders-Brown Center on Aging, University of Kentucky, Lexington (Van Eldik); Alzheimer Disease Center, University of Michigan, Ann Arbor (Paulson); Department of Pathology and Laboratory Medicine. University of Pennsylvania, Philadelphia (Trojanowski); University of Southern California, Los Angeles (Chui); University of Texas Southwestern Medical Center, Dallas (Rosenberg); Wake Forest School of Medicine, Winston-Salem, North Carolina (Craft); Department of Radiology, University of Washington, Seattle (Grabowski): Department of Neurology, University of Washington, Seattle (Grabowski); University of Wisconsin, Madison (Asthana); Department of Neurology, Washington University School of Medicine, St Louis, Missouri (Morris); Department of Neurology, Yale University School of Medicine, New Haven, Connecticut (Strittmatter); National Alzheimer's Coordinating Center, University of Washington, Seattle (Kukull); Department of Epidemiology, University of Washington, Seattle (Kukull).

Author Contributions: Drs Kunkle and Reitz had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Kunkle, Lunetta, Goate, Haines, Pericak-Vance, Reitz. Acquisition, analysis, or interpretation of data: Kunkle, Schmidt, Klein, Naj, Hamilton-Nelson, Larson, Graff-Radford, Evans, De Jager, Martinez, Ayodele, Crane, Buxbaum, Ertekin-Taner, Logue, Barnes, Cantwell, Jean-Francois, Kuzma, Adams, Fallin, Vance, Cuccaro, Manly, Chung, Mez, Go, Obisesan, Jun, Kamboh, Lopez, Bennett, Hall, Hendrie, Reiman, Kowall, Leverenz, Small, Levey, Golde, Saykin, Starks, Albert, Hyman, Petersen, Sano, Wisniewski, Vassar, Kaye, Henderson, DeCarli, LaFerla, Brewer, Miller, Swerdlow, Van Eldik, Paulson, Trojanowski, Chui, Rosenberg,

Craft, Grabowski, Asthana, Morris, Strittmatter, Kukull, Foroud, Martin, Wang, Byrd, Farrer, Haines, Schellenberg, Mayeux, Pericak-Vance, Reitz, Drafting of the manuscript: Kunkle, Klein, Hamilton-Nelson, Adams, Chung, Small, LaFerla, Miller, Goate, Schellenberg, Reitz. Critical revision of the manuscript for important intellectual content: Kunkle, Schmidt, Klein, Nai, Larson, Graff-Radford, Evans, De Jager, Martinez, Avodele, Crane, Buxbaum, Ertekin-Taner, Logue, Barnes, Cantwell, Jean-Francois, Kuzma, Fallin, Vance, Cuccaro, Manly, Mez, Go, Obisesan, Lunetta, Jun, Kamboh, Lopez, Bennett, Hall, Hendrie, Reiman, Kowall, Leverenz, Levey, Golde, Saykin, Starks, Albert, Hyman, Petersen, Sano, Wisniewski, Vassar, Kaye, Henderson, DeCarli, Brewer, Swerdlow, Van Eldik, Paulson, Trojanowski, Chui, Rosenberg, Craft, Grabowski, Asthana, Morris, Strittmatter, Kukull, Foroud, Martin, Wang, Byrd, Farrer, Haines, Mayeux, Pericak-Vance, Reitz. Statistical analysis: Kunkle, Schmidt, Klein, Naj, Hamilton-Nelson, De Jager, Logue, Jean-Francois, Jun, Trojanowski, Haines, Reitz. Obtained funding: Larson, Evans, Crane, Buxbaum,

Ertekin-Taner, Fallin, Manly, Go, Kamboh, Lopez, Bennett, Hall, Reiman, Leverenz, Small, Hyman, Petersen, Wisniewski, Rosenberg, Grabowski, Morris, Strittmatter, Wang, Farrer, Haines, Mayeux, Pericak-Vance, Reitz.

Administrative, technical, or material support: Naj, Larson, Evans, Martinez, Ayodele, Crane, Ertekin-Taner, Cantwell, Kuzma, Go, Obisesan, Kamboh, Lopez, Hall, Hendrie, Reiman, Kowall, Levey, Golde, Starks, Wisniewski, Vassar, Kaye, DeCarli, Swerdlow, Van Eldik, Chui, Kukull, Foroud, Martin, Wang, Byrd, Schellenberg, Mayeux. *Supervision:* Kunkle, Vance, Obisesan, Lunetta, Kamboh, Bennett, Sano, Miller, Trojanowski, Rosenberg, Morris, Strittmatter, Mayeux, Pericak-Vance, Reitz.

Conflict of Interest Disclosures: Dr Kunkle reported grants from the National Institute of Aging (NIA) during the conduct of the study. Dr Schmidt reported grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Larson reported grants from NIA during the conduct of the study. Dr Graff-Radford reported grants from NIH during the conduct of the study; grants from AbbVie, Biogen, Eli Lilly and Company, and Novartis outside the submitted work. Dr Evans reported grants from NIH during the conduct of the study. Dr Vance reported grants from NIH/NIA during the conduct of the study. Dr Cuccaro reported grants from NIH during the conduct of the study and other support from John P. Hussman Foundation outside the submitted work. Dr Manly reported grants from NIA/NIH during the conduct of the study. Dr Mez reported grants from NIH during the conduct of the study. Dr Obisesan reported grants from NIH during the conduct of the study. Dr Bennett reported grants from NIH during the conduct of the study. Dr Hall reported grants from NIA during the conduct of the study. Dr Reiman reported grants from Banner Alzheimer's Institute during the conduct of the study other support from Roche/Roche Diagnostics outside the submitted work. Dr Leverenz reported grants from NIA during the conduct of the study and grants from Alzheimer's Drug Discovery Foundation, Avid Biopharmaceuticals, Biogen, GE Healthcare, Lewy Body Dementia Association, Michael J. Fox Foundation, National Institute of Neurologic Disorders, and Stroke, Sanofi: and consulting fees from Acadia, Aptinyx, Biogen, Eisai, Genzyme, Sanofi, and Takeda. Dr Levey reported personal fees from Karuna Pharmaceuticals and GENUV and grants from vTv Therapeutics, AbbVie, Biogen, Cognito, Esai, Genentech, and Novartis outside the submitted work. Dr Golde reported personal fees from Biogen. Eli Lilly and Company, and AbbVie; nonfinancial support from Lacerta Therapeutics outside the submitted work: and served on safety advisory boards for AbbVie, Promis Therapeutics, Biogen, and Eli Lilly and company. Dr Savkin reported grants from NIH grants during the conduct of the study and other support from Springer-Nature and grants from Eli Lilly and Company; multiprincipal investigator of NIA Small Business Innovation Research to Arkley BioTek, consultant to Bayer Oncology, and served on the advisory board of Neurovision outside the submitted work. Dr Albert reported grants from NIA during the conduct of the study and personal fees from Eli Lilly and Company outside the submitted work. Dr Hyman reported grants from NIH during the conduct of the study. Dr Petersen reported grants from NIH during the conduct of the study and personal fees from Hoffman-La Roche, Merck, Genentech, Biogen, GE Healthcare, and Eisai outside the submitted work. Dr Wisniewski reported grants from NIH during the conduct of the study and outside the submitted work. Dr Kaye reported grants from NIH during the conduct of the study. Dr Henderson reported grants from NIH during the conduct of the study. Dr DeCarli reported consulting for Novartis Pharmaceutical on a safety study in heart failure. Dr Brewer reported holds stock options in CorTechs Labs and Human Longevity and has served on advisory boards for Human Longevity and Eli Lilly and Company outside the submitted work. Dr Van Eldik reported grants from NIH during the conduct of the study. Dr Chui reported grants from NIA during the conduct of the study. Dr Rosenberg reported other support from Vitruvian during the conduct of the study; grants from NIH/ NIA, Zale Foundation, AWARE, Triumph over Alzheimer's Disease, and Its Their Time outside the submitted work; has a patent to amyloid beta gene vaccines issued; and served as a former Editor of JAMA Neurology, editorial board of The Journal of the Neurological Sciences, and former editorial board member of JAMA. Dr Grabowski reported grants from NIH during the conduct of the study. Dr Asthana reported grants from NIA during the conduct of the study and grants from Genentech and Lundbeck outside the submitted work. Dr Morris reported grants from NIH during the conduct of the study. Dr Strittmatter reported being a founder and equity holder in ReNetX Bio and in Allyx Therapeutics, entities seeking to develop therapeutics for Neural Repair and Neurodegeneration, respectively. Dr Goate served on the scientific advisory board for Denali Therapeutics from 2015-2018 and has served as a consultant for Biogen, AbbVie, Pfizer, GlaxoSmithKline, Eisai, and Illumina. Dr Kukull reported grants from NIH/NIA during the conduct of the study. Dr Foroud reported grants from NIH during the conduct of the study. Dr Haines reported grants from NIH during the conduct of the study. Dr Schellenberg reported grants from University of Pennsylvania during the conduct of the study. Dr Pericak-Vance reported grants from NIH/NIA during the conduct of the study. Dr Reitz reported grants from NIH during the conduct of the study. No other disclosures were reported.

Funding/Support: This study was supported by the National Institutes of Health (NIH) (grants RF1 AG054023, U24 AG056270), Alzheimer's Disease Genetics Consortium (grant U01 AG032984),

National Institute on Aging (NIA) Genetics Initiative for Late-Onset Alzheimer's Disease (grants U24 AG026395. U24 AG026390 [PI. Richard Mayeux. MD]), NIA Genetics of Alzheimer's Disease Data Storage Site (grant U24 AGO41689 [PI, Li-San Wang, PhD]), Washington Heights-Inwood Community Aging Project (grant R01 AG037212, R37 AG015473 [PI. Richard Mayeux, MD]). National Centralized Repository for Alzheimer's Disease and Related Dementias (grant U24 AGO21886 [PI. Tatiana Foroud, PhD]), Indianapolis AA (grants RO1 AG009956, RC2 AG036650 [PI, Kathleen Hall, PhD]), ACT (grants U01 AG06781, U01 HG004610 [PI, Eric Larson, MD, MPH]), MIRAGE (grant R01 AG009029 [PI, Lindsay Farrer, PhD]), GenerAAtions (grant 5R01 AG20688 [PI, M. Daniele Fallin, PhD]), Pittsburg (grants P50 AG005133 [PI, O. Lopez], AG030653, AG041718, AG064877 [PI, M. Ilyas Kamboh, PhD]), Case Western Reserve University (grant RO1 AGO19085 [PI, Jonathan Haines, PhD]), CHAP (grants RO1 AG11101, RO1 AG030146, RC2 AG036650 [PI, Denis Evans, MD]), ROS/MAP (grants P30 AG10161, R01 AG15819, R01 AG30146, R01 AG17917, R01 AG15819 [PI, David Bennett, MD]), African-American AD Genetics Study (grant RO1 AGO28786 [PI, Jennifer Manly, PhD]), MARS/CORE (grants R01 AG22018, P30 AG10161 [PI, Lisa Barnes, PhD]), Mayo Clinic (grants P50 AG0016574, R01 032990, KL2 RR024151 [PIs, Ronald C. Petersen, MD. PhD. Nilufer Ertekin-Taner. MD, PhD, and Neill Graff-Radford, MD]), Miami (grants R01 AG027944, R01 AG028786 [PI, Margaret Pericak-Vance, PhD1), Wake Forest (PI, Goldie Byrd, PhD), MSSM (PI, Joseph Buxbaum, PhD), and MSSM (grants P50 AG05681, P01 AG03991, P01 AG026276 [PI, Alison Goate]). Dr Reitz was further supported by the NIH (grants RF1AG054080. U01AG052410. AG0087202). The NACC database is funded by NIA/NIH (grant UO1 AG016976). National Alzheimer's Coordinating Center data are contributed by the NIA-funded Alzheimer Disease Centers (grants P30 AG019610 [PI, Eric Reiman, MD], P30 AG013846 [PI, Neil Kowall, MD], P30 AG062428-01 [PI, James Leverenz, MD], P50 AG008702 [PI, Scott Small, MD], P50 AG025688 [PI, Allan Levey, MD, PhD], P50 AG047266 [PI, Todd Golde, MD, PhD], AG045058 [PI, Thomas Obisesan, MD, MPH], P30 AG010133 [PI, Andrew Saykin, PsyD], P50 AG005146 [PI. Marilvn Albert, PhD], P30 AG062421-01 [PI, Bradley Hyman, MD, PhD], P50 AG005138 [PI, Mary Sano, PhD], P30 AG008051 [PI, Thomas Wisniewski, MD], P30 AG013854 [PI, Robert Vassar, PhD], P30 AG008017 [PI, Jeffrey Kaye, MD], P30 AG010161 [PI, David Bennett, MD], P50 AG047366 [PI, Victor Henderson, MD, MS], P30 AG010129 [PI, Charles DeCarli, MD], P50 AG016573 [PI, Frank LaFerla, PhD], P30 AG062429-01 [PI, James Brewer, MD, PhD], P50 AG023501 [PI, Bruce Miller, MD], P30 AG035982 [PI, Russell Swerdlow, MD], P30 AG028383 [PI, Linda Van Eldik, PhD], P30 AG053760 [PI, Henry Paulson, MD, PhD], P30 AG010124 [PI, John Trojanowski, MD, PhD], P50 AG005133 [PI, Oscar Lopez, MD], P50 AG005142 [PI, Helena Chui, MD], P30 AG012300 [PI, Roger Rosenberg, MD], P30 AG049638 [PI, Suzanne Craft, PhD], P50 AG005136 [PI, Thomas Grabowski, MD], P30 AGO62715-01 [PI, Sanjay Asthana, MD, FRCP], P50 AG005681 [Pl. John C. Morris, MD], P50 AGO47270 [PI, Stephen Strittmatter, MD, PhD]).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study;

collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The Alzheimer's Disease Genetics Consortium (ADGC) collaborators are listed in Supplement 2.

REFERENCES

1. Seshadri S, Fitzpatrick AL, Ikram MA, et al; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010; 303(18):1832-1840. doi:10.1001/jama.2010.574

2. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet*. 2011;43(5):436-441. doi:10. 1038/ng.801

3. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet*. 2009;41(10):1088-1093. doi:10.1038/ng.440

4. Hollingworth P, Harold D, Sims R, et al; Alzheimer's Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet*. 2011;43(5):429-435. doi:10.1038/ng.803

5. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med*. 2013;368(2): 107-116. doi:10.1056/NEJMoa1211103

6. Lambert JC, Heath S, Even G, et al; European Alzheimer's Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet*. 2009;41(10):1094-1099. doi:10.1038/ng.439

7. Kunkle BW, Grenier-Boley B, Sims R, et al Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet*. 2019;51(3): 414-430. doi:10.1038/s41588-019-0358-2

 Sims R, van der Lee SJSJ, Naj ACACAC, et al; ARUK Consortium; GERAD/PERADES, CHARGE, ADGC, EADI. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nat Genet*. 2017; 49(9):1373-1384. doi:10.1038/ng.3916

9. Ridge PG, Mukherjee S, Crane PK, Kauwe JS; Alzheimer's Disease Genetics Consortium. Alzheimer's disease: analyzing the missing heritability. *PLoS One*. 2013;8(11):e79771. doi:10. 1371/journal.pone.0079771

10. So HC, Gui AH, Cherny SS, Sham PC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. *Genet Epidemiol.* 2011;35(5):310-317. doi:10.1002/gepi.20579

11. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry*. 2006;63(2):168-174. doi:10.1001/archpsyc.63.2.168

12. Tang M-X, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. *Neurology*. 2001;56(1):49-56. doi:10.1212/WNL.56.1.49

13. Hohman TJ, Cooke-Bailey JN, Reitz C, et al; Alzheimer Disease Genetics Consortium. Global and local ancestry in African-Americans: implications for Alzheimer's disease risk. *Alzheimers Dement*. 2016; 12(3):233-243. doi:10.1016/j.jalz.2015.02.012

14. Reitz C, Jun G, Naj A, et al; Alzheimer Disease Genetics Consortium. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ 4,and the risk of late-onset Alzheimer disease in African Americans. *JAMA*. 2013;309(14):1483-1492. doi:10.1001/jama.2013.2973

15. Reitz C, Mayeux R; Alzheimer's Disease Genetics Consortium. TREM2 and neurodegenerative disease. *N Engl J Med.* 2013;369 (16):1564-1565. doi:10.1056/NEJMc1306509

16. Rajabli F, Feliciano BE, Celis K, et al. Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations. *PLoS Genet*. 2018;14(12):e1007791. doi:10.1371/journal.pgen. 1007791

17. Jin SC, Carrasquillo MM, Benitez BA, et al. TREM2 is associated with increased risk for Alzheimer's disease in African Americans. *Mol Neurodegener*. 2015;10(1):19. doi:10.1186/s13024-015-0016-9

18. Cukier HN, Kunkle BW, Vardarajan BN, et al; Alzheimer's Disease Genetics Consortium. ABCA7 frameshift deletion associated with Alzheimer disease in African Americans. *Neurol Genet*. 2016;2 (3):e79. doi:10.1212/NXG.0000000000000079

19. N'Songo A, Carrasquillo MM, Wang X, et al. African American exome sequencing identifies potential risk variants at Alzheimer disease loci. *Neurol Genet*. 2017;3(2):e141. doi:10.1212/NXG. 000000000000141

20. Logue MW, Schu M, Vardarajan BN, et al; Alzheimer Disease Genetics Consortium; Alzheimer Disease Genetics Consortium. Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. *Alzheimers Dement*. 2014;10(6): 609-618.e11. doi:10.1016/j.jalz.2014.06.010

21. Mez J, Chung J, Jun G, et al; Alzheimer's Disease Genetics Consortium. Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. *Alzheimers Dement*. 2017;13(2):119-129. doi:10.1016/j.jalz.2016.09.002

22. Santos OA, Pedraza O, Lucas JA, et al. Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort. *Alzheimers Dement*. 2019;15(5):635-643. doi:10.1016/j.jalz.2018.12.013

23. Barnes LL, Leurgans S, Aggarwal NT, et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. *Neurology*. 2015;85(6):528-534. doi:10.1212/WNL. 00000000001834

24. Morris JC, Schindler SE, McCue LM, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. *JAMA Neurol*. 2019;76(3):264-273. doi:10.1001/jamaneurol.2018.4249

25. Filshtein TJ, Dugger BN, Jin LW, et al. Neuropathological diagnoses of demented Hispanic, Black, and non-Hispanic white decedents seen at an Alzheimer's disease center. *J Alzheimers Dis*. 2019;68(1):145-158. doi:10.3233/JAD-180992

26. Graff-Radford NR, Besser LM, Crook JE, Kukull WA, Dickson DW. Neuropathologic differences by race from the National Alzheimer's Coordinating Center. *Alzheimers Dement*. 2016;12(6):669-677. doi:10.1016/j.jalz.2016.03.004

27. The African Partnership for Chronic Disease Research. Data. Accessed September 4, 2020. https://www.apcdr.org/data/ 28. Blacker D, Bertram L, Saunders AJ, et al; NIMH Genetics Initiative Alzheimer's Disease Study Group. Results of a high-resolution genome screen of 437 Alzheimer's disease families. *Hum Mol Genet*. 2003;12(1):23-32. doi:10.1093/hmg/ddg007

29. Guerreiro R, Wojtas A, Bras J, et al; Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. *N Engl J Med*. 2013;368(2):117-127. doi:10.1056/NEJMoa1211851

30. NIAGADS. Explore genetics and genomics of Alzheimer's Disease. Accessed September 4, 2020. https://www.niagads.org/

31. Yu L, Chibnik LB, Srivastava GP, et al. Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. *JAMA Neurol*. 2015;72(1):15-24. doi:10.1001/jamaneurol. 2014.3049

32. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput Biol*. 2015;11(4):e1004219. doi: 10.1371/journal.pcbi.1004219

33. International Genomics of Alzheimer's Disease Consortium (IGAP); Jones L, Lambert J-C, Wang L-S, et al. Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimers Dement*. 2015;11(6). doi:10.1016/j.jalz. 2014.05.1757

34. Lambert J-C, Ibrahim-Verbaas CA, Harold D, et al; European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet*. 2013;45(12):1452-1458. doi:10.1038/ng.2802

35. Cummings AC, Jiang L, Velez Edwards DR, et al. Genome-wide association and linkage study in the Amish detects a novel candidate late-onset Alzheimer disease gene. *Ann Hum Genet*. 2012;76 (5):342-351. doi:10.1111/j.1469-1809.2012.00721.x

36. Lamriben L, Oster ME, Tamura T, et al. EDEMI's mannosidase-like domain binds ERAD client proteins in a redox-sensitive manner and possesses catalytic activity. *J Biol Chem*. 2018;293(36):13932-13945. doi:10.1074/jbc.RA118.004183

37. Molinari M, Calanca V, Galli C, Lucca P, Paganetti P. Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle. *Science*. 2003;299(5611):1397-1400. doi:10.1126/ science.1079474

 Cormier JH, Tamura T, Sunryd JC, Hebert DN.
 EDEM1 recognition and delivery of misfolded proteins to the SEL1L-containing ERAD complex. *Mol Cell*. 2009;34(5):627-633. doi:10.1016/j.molcel.
 2009.05.018

39. Kaneko M, Koike H, Saito R, Kitamura Y, Okuma Y, Nomura Y. Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. *J Neurosci.* 2010;30(11):3924-3932. doi:10.1523/JNEUROSCI.2422-09.2010

40. Kamboh MI, Fan KH, Yan Q, et al. Population-based genome-wide association study of cognitive decline in older adults free of dementia: identification of a novel locus for the attention domain. *Neurobiol Aging*. 2019;84:239.e15-239.e24. doi:10.1016/j.neurobiolaging.2019.02.024

41. Allen NJ, Bennett ML, Foo LC, et al. Astrocyte glypicans 4 and 6 promote formation of excitatory

synapses via GluA1 AMPA receptors. *Nature*. 2012; 486(7403):410-414. doi:10.1038/nature11059

42. Kang TH, Kim KT. Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase. *Nat Cell Biol.* 2006;8(8):863-869. doi:10.1038/ncb1447

43. Wu GY, Deisseroth K, Tsien RW. Spaced stimuli stabilize MAPK pathway activation and its effects on dendritic morphology. *Nat Neurosci.* 2001;4(2): 151-158. doi:10.1038/83976

44. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. *Nat Rev Neurosci*. 2004;5(3):173-183. doi:10.1038/nrn1346

45. Song H, Kim W, Kim SH, Kim KT. VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and A β accumulation via enhancement of ERK phosphatase VHR activity. *Sci Rep.* 2016;6: 38452. doi:10.1038/srep38452

46. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. *Lancet Neurol*. 2003;2(8): 482-492. doi:10.1016/S1474-4422(03)00484-8

47. van Horssen J, Otte-Höller I, David G, et al. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. *Acta Neuropathol*. 2001;102(6):604-614. doi:10.1007/ s004010100414

48. van Horssen J, Kleinnijenhuis J, Maass CN, et al. Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. *Neurobiol Aging*. 2002;23(4):537-545. doi:10.1016/ S0197-4580(02)00010-6

49. Beckman M, Holsinger RM, Small DH. Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. *Biochemistry*. 2006;45(21):6703-6714. doi:10.1021/bi052498t

50. Leveugle B, Ding W, Durkin JT, et al. Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein. *Neurochem Int*. 1997;30(6):543-548. doi:10.1016/S0197-0186 (96)00103-9

 Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. *J Neurochem*. 1997;69(6):2452-2465. doi:10.1046/j. 1471-4159.1997;69062452.x

52. Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. Preprint posted online August 13, 2019. doi: 10.1101/531210

53. Tatsuoka C, Tseng H, Jaeger J, et al; Alzheimer's Disease Neuroimaging Initiative. Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment. *Alzheimers Res Ther.* 2013;5(2):14. doi:10.1186/alzrt168

54. Zhang H, Zhou H, Lencz T, Farrer LA, Kranzler HR, Gelernter J. Genome-wide association study of cognitive flexibility assessed by the Wisconsin Card Sorting Test. *Am J Med Genet B Neuropsychiatr Genet.* 2018;177(5):511-519. doi:10.1002/ajmg.b.32642

55. Holzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. *Nature*. 2003;421(6919): 182-187. doi:10.1038/nature01298

56. Talbot K, Wang H-Y, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. *J Clin Invest*. 2012;122(4):1316-1338. doi:10.1172/JCI59903

57. Freude S, Hettich MM, Schumann C, et al. Neuronal IGF-1 resistance reduces A beta accumulation and protects against premature death in a model of Alzheimer's disease. *FASEB J*. 2009;23(10):3315-3324. doi:10.1096/fj.09-132043

58. De Magalhaes Filho CD, Kappeler L, Dupont J, et al. Deleting IGF-1 receptor from forebrain neurons confers neuroprotection during stroke and upregulates endocrine somatotropin. J Cereb Blood Flow Metab. 2017;37(2):396-412. doi:10.1177/ 0271678X15626718

59. Cohen E, Paulsson JF, Blinder P, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. *Cell*. 2009;139(6):1157-1169. doi:10.1016/j. cell.2009.11.014

60. Gontier G, George C, Chaker Z, Holzenberger M, Aïd S. Blocking IGF signaling in adult neurons alleviates Alzheimer's Disease pathology through amyloid-β clearance. *J Neurosci.* 2015;35(33): 11500-11513. doi:10.1523/JNEUROSCI.0343-15.2015

61. Garcia-Jove Navarro M, Basset C, Arcondéguy T, et al. Api5 contributes to E2F1 control of the G1/S cell cycle phase transition. *PLoS One*. 2013;8(8): e71443. doi:10.1371/journal.pone.0071443

62. Auweter SD, Fasan R, Reymond L, et al. Molecular basis of RNA recognition by the human alternative splicing factor Fox-1. *EMBO J*. 2006;25 (1):163-173. doi:10.1038/sj.emboj.7600918

63. Hamada N, Ito H, Iwamoto I, Morishita R, Tabata H, Nagata K. Role of the cytoplasmic isoform of RBFOX1/A2BP1 in establishing the architecture of the developing cerebral cortex. *Mol Autism.* 2015; 6:56. doi:10.1186/s13229-015-0049-5

64. Gandal MJ, Zhang P, Hadjimichael E, et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. *Science*. 2018;362(6420):eaat8127. doi:10.1126/ science.aat8127

65. Alkallas R, Fish L, Goodarzi H, Najafabadi HS. Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer's disease. *Nat Commun*. 2017;8(1):909. doi:10.1038/s41467-017-00867-z

66. Lee JA, Damianov A, Lin CH, et al. Cytoplasmic Rbfox1 regulates the expression of synaptic and autism-related genes. *Neuron*. 2016;89(1):113-128. doi:10.1016/j.neuron.2015.11.025

67. Alam S, Suzuki H, Tsukahara T. Alternative splicing regulation of APP exon 7 by RBFox

proteins. Neurochem Int. 2014;78:7-17. doi:10.1016/ j.neuint.2014.08.001

68. Raghavan NS, Dumitrescu L, Mormino E, et al; Alzheimer's Disease Neuroimaging Initiative. Association between common variants in RBFOX1, an RNA-binding protein, and brain amyloidosis in early and preclinical Alzheimer disease. *JAMA Neurol.* Published online June 22, 2020. doi:10.1001/ jamaneurol.2020.1760

69. Forstner AJ, Hecker J, Hofmann A, et al. Identification of shared risk loci and pathways for bipolar disorder and schizophrenia. *PLoS One*. 2017; 12(2):e0171595. doi:10.1371/journal.pone.0171595

70. Chen DT, Jiang X, Akula N, et al; BiGS. Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder. *Mol Psychiatry*. 2013;18(2):195-205. doi:10.1038/mp.2011.157

71. Ruderfer DM, Fanous AH, Ripke S, et al; Schizophrenia Working Group of the Psychiatric Genomics Consortium; Bipolar Disorder Working Group of the Psychiatric Genomics Consortium; Cross-Disorder Working Group of the Psychiatric Genomics Consortium. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. *Mol Psychiatry*. 2014;19(9): 1017-1024. doi:10.1038/mp.2013.138

72. Goes FS, Hamshere ML, Seifuddin F, et al; Bipolar Genome Study (BiGS). Genome-wide association of mood-incongruent psychotic bipolar disorder. *Transl Psychiatry*. 2012;2:e180. doi:10. 1038/tp.2012.106

73. Jiang X, Detera-Wadleigh SD, Akula N, et al. Sodium valproate rescues expression of TRANK1 in iPSC-derived neural cells that carry a genetic variant associated with serious mental illness. *Mol Psychiatry*. 2019;24(4):613-624. doi:10.1038/s41380-018-0207-1

74. Laster M, Shen JI, Norris KC. Kidney disease among African Americans: a population perspective. *Am J Kidney Dis*. 2018;72(5)(suppl 1): S3-S7. doi:10.1053/j.ajkd.2018.06.021

75. McAdams-DeMarco MA, Daubresse M, Bae S, Gross AL, Carlson MC, Segev DL. Dementia, Alzheimer's disease, and mortality after hemodialysis initiation. *Clin J Am Soc Nephrol*. 2018; 13(9):1339-1347. doi:10.2215/CJN.10150917

76. Pirici D, Stanaszek L, Garz C, et al. Common impact of chronic kidney disease and brain microhemorrhages on cerebral A β pathology in SHRSP. *Brain Pathol*. 2017;27(2):169-180. doi:10. 1111/bpa.12384

77. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266-273. doi:10.1097/NEN. 0b013e31824b211b

78. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. *Curr Alzheimer Res.* 2012;9(6):628-645. doi:10.2174/156720512801322573